These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 27561807)

  • 1. [Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations].
    Wang Q; Zheng H; Hu F; Zhang H; Hu Y; Li J; Zhang T; Liu Z; Lu B; Hu A; Li B
    Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):550-8. PubMed ID: 27561807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
    J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.
    Takeuchi A; Oguri T; Sone K; Ito K; Kitamura Y; Inoue Y; Asano T; Fukuda S; Kanemitsu Y; Takakuwa O; Ohkubo H; Takemura M; Maeno K; Ito Y; Niimi A
    Anticancer Res; 2017 Oct; 37(10):5771-5776. PubMed ID: 28982900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].
    Chen H; Yang X; Liu H; Ma K; Zhong J; Dong Z; Zhuo M; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
    Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):589-597. PubMed ID: 28935011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients.
    Facchinetti F; Aldigeri R; Aloe R; Bortesi B; Ardizzoni A; Tiseo M
    Tumour Biol; 2015 Aug; 36(8):5943-51. PubMed ID: 25731731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
    Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
    J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.
    Jiang R; Wang X; Li K
    Oncotarget; 2016 May; 7(18):26823-36. PubMed ID: 27072585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
    Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
    BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
    Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of carcinoembryonic antigen levels in predicting the efficacy of EGFR-TKI in advanced non-small cell lung cancer harboring EGFR mutations].
    Jin B; Zhang Y; Zhang X; Li R; Lou Y; Niu Y; Huang A; Han B
    Zhonghua Yi Xue Za Zhi; 2014 Aug; 94(30):2327-31. PubMed ID: 25399971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
    Schuette W; Schirmacher P; Eberhardt WEE; Dietel M; Zirrgiebel U; Muehlenhoff L; Thomas M
    BMC Cancer; 2018 Feb; 18(1):135. PubMed ID: 29402243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
    Xu J; Jin B; Chu T; Dong X; Yang H; Zhang Y; Wu D; Lou Y; Zhang X; Wang H; Han B
    Lung Cancer; 2016 Jun; 96():87-92. PubMed ID: 27133756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
    Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y
    Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Variations in Serum CEA and CYFRA21-1 Levels Before and After Surgery Facilitate Prognosis of Non-small Cell Lung Cancer Patients].
    Duan X; Cui Y; Gong M; Tian F; Shi G; Wu B; Liu M; Guo J; Kong Y
    Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):358-64. PubMed ID: 26104892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations.
    Yanwei Z; Bo J; Yuqing L; Rong L; Xueyan Z; Song H; Baohui H
    J Cancer Res Ther; 2016; 12(1):254-8. PubMed ID: 27072247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.